Isaac Francis

Flowserve Corporation (NYSE:FLS), a major global provider of flow control products and services for infrastructure markets, has announced that its Board of Directors has authorized a quarterly cash dividend of $0.21 per share on the company’s outstanding common stock.

Strategy retained its position in the Nasdaq 100 following the index’s annual rebalancing, marking its first successful review since joining the benchmark in December last year and signalling continued acceptance by major equity indices.

The company, formerly known as MicroStrategy, stood out during the rebalance due to its unconventional balance sheet, which is heavily weighted towards Bitcoin (CRYPTO:BTC) rather than traditional operating assets.

The global stablecoin market reached a new all-time high in the second week of December, surpassing $310 billion as fiat-pegged tokens regained momentum.

Data from DefiLlama shows the stablecoin sector peaked at approximately $310.09 billion on Saturday, marking its strongest level to date.

Rhythm Biosciences (ASX:RHY) has commenced commercialisation of its flagship blood-based colorectal cancer test, ColoSTAT, following the update and renewal of its ISO15189:2022 laboratory accreditation.

The test will initially be offered as an alternative for symptomatic individuals where stool-based screening is unsuitable, unavailable, or not preferred, addressing a significant unmet clinical need.

ABx Group (ASX:ABX) has been granted a new five-year exploration licence, EL25/2022, strengthening its position in a highly prospective rare earths region in northern Tasmania.

The 18km2 tenement sits between the company's Rubble Mound and Wind Break deposits, part of ABx's 89-million-tonne resource averaging 844 ppm total rare earth oxides.

Metallium (ASX:MTM) announced that its US subsidiary, Flash Metals USA, has signed a binding letter of intent with ElementUSA to collaborate on the recovery of gallium and scandium from red mud at the Gramercy alumina refinery in Louisiana.

Ciena® Corporation (NYSE:CIEN) today announced its financial results for the fiscal fourth quarter and full year ended November 1, 2025.

For the fiscal fourth quarter of 2025, Ciena reported revenue of $1.35 billion, reflecting a 20% increase year-over-year.

For the full fiscal year 2025, the company generated $4.77 billion in revenue, marking a 19% year-over-year growth.

Zedge (NYSE:ZDGE) announced its financial results for the first quarter of fiscal 2026, ended October 31, 2025.

The company reported revenue of $7.6 million, reflecting a 5.8% year-over-year increase.

Save the Children has unveiled a first-of-its-kind Bitcoin (CRYPTO:BTC) Fund in partnership with digital asset firm Fortris to modernise humanitarian aid.

The fund allows the organisation to hold Bitcoin donations for up to four years under a “hodl” strategy to maximise long-term value.

OKYO Pharma (NASDAQ:OKYO) announced on December 11, 2025, new analyses from its Phase 2, placebo-controlled, randomized, double-masked trial of 0.05% urcosimod for the treatment of neuropathic corneal pain (NCP).

The trial, involving 18 patients, provided exploratory data on corneal nerve imaging using in vivo confocal microscopy.